Turning Point Brands, Inc.
88.16-0.69 (-0.78%)
Oct 29, 4:00:02 PM EDT · NYSE · TPB · USD
Key Stats
Market Cap
1.59BP/E (TTM)
31.49Basic EPS (TTM)
2.80Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
Turning Point Brands posted solid Q2 results, with net sales jumping 25.1% year-over-year to $116.6M, fueled by a 62.9% surge in the Stoker's segment to $69.6M from modern oral product growth, while Zig-Zag dipped 6.9% to $47.0M amid softer papers and cigars. Gross margins expanded to 57.1% from 54.1%, lifting operating income 15.1% to $26.3M, though diluted EPS edged up modestly to $0.79 from $0.68, reconciling cleanly with 18.3M shares. Free cash flow hit $23.1M (derived), bolstering cash to $109.9M alongside $66.5M ABL availability, but debt climbed to $293.1M after swapping $250M 2026 notes for $300M 2032 notes at 7.625%. The CDS segment wrapped up in January via joint venture contribution for 49% equity stake. Yet regulatory pressures from FDA enforcement priorities loom large.
8-K
Q2 sales up 25%, guidance raised
Turning Point Brands reported Q2 2025 net sales surging 25.1% to $116.6 million, fueled by Modern Oral's explosive 651% growth to $30.1 million, now 26% of total. Adjusted EBITDA climbed 14.8% to $30.5 million, while Zig-Zag dipped 6.9%. The company raised full-year guidance to $110–114 million Adjusted EBITDA and $100–110 million Modern Oral sales. Momentum builds, yet FDA PMTA costs linger.
8-K
Annual meeting results announced
Turning Point Brands held its annual stockholder meeting on May 6, 2025, electing all nine director nominees with strong support, averaging over 12 million votes for amid 239,000 withheld. Shareholders approved an amendment limiting liability for certain officers and ratified KPMG as auditors for 2025, with near-unanimous backing. Say-on-pay passed handily. All directors secured their seats.
10-Q
Q1 FY2025 results
Turning Point Brands kicked off 2025 with net sales climbing 28.1% year-over-year to $106.4M for the quarter ended March 31, fueled by a 62.7% surge in Stoker's products to $59.2M from modern oral and MST gains, while Zig-Zag held steady at $47.3M. Gross margins dipped to 56.0% from 58.2%, yet operating income rose 20.3% to $23.2M, with diluted EPS up to $0.79 from $0.63 on 18.2M shares. Free cash flow hit $15.2M (derived), bolstering cash to $99.6M; debt shifted to $300M 7.625% notes due 2032, with $62.2M ABL availability. On January 2, contributed CDS unit to GWO JV for 49% stake, recognizing $10.5M noncash investment. Solid momentum persists. But FDA flavor bans loom large.
8-K
Q1 sales soar 28% on oral boom
Turning Point Brands reported Q1 2025 net sales surging 28.1% to $106.4 million, fueled by Stoker's Products jumping 62.7% to $59.2 million on explosive Modern Oral growth to $22.3 million—nearly tenfold year-over-year. Adjusted EBITDA climbed 12.0% to $27.7 million, despite higher SG&A from FDA PMTA costs and debt refinancing. The company reaffirmed $108.0–113.0 million full-year Adjusted EBITDA guidance while lifting Modern Oral sales outlook to $80.0–95.0 million. Refinancing swapped $250 million 2026 notes for $300 million 2032 notes, extending maturities amid regulatory pressures.
IPO
Employees
Sector
Industry
BTI
British American Tobacco Indus
51.72-0.74
CHUC
Charlie's Holdings, Inc.
0.27-0.01
ISPR
Ispire Technology Inc.
2.26+0.15
KAVL
Kaival Brands Innovations Group
0.57-0.01
MO
Altria Group, Inc.
61.97-1.31
NBND
NetBrands Corp.
0.00+0.00
PM
Philip Morris International Inc
146.77-3.04
TLRY
Tilray Brands, Inc.
1.36-0.02
TOBAF
TAAT Global Alternatives Inc.
0.09+0.02
VPRB
VPR Brands, LP
0.05+0.00